CanSino Biologics (Germany) Insiders
| CJH Stock | 3.66 0.12 3.17% |
CanSino Biologics employs about 9 people. The company is managed by 9 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down CanSino Biologics' management performance can provide insight into the firm performance.
| Xuefeng Yu Chairman Chairman, CoFounder |
CanSino |
CanSino Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0207) % which means that it has lost $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0111 %, meaning that it generated $0.0111 on every $100 dollars invested by stockholders. CanSino Biologics' management efficiency ratios could be used to measure how well CanSino Biologics manages its routine affairs as well as how well it operates its assets and liabilities.CanSino Biologics Workforce Comparison
CanSino Biologics is rated second in number of employees category among its peers. The total workforce of Drug Manufacturers-Specialty & Generic industry is currently estimated at about 34,603. CanSino Biologics adds roughly 9.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers-Specialty & Generic industry.
CanSino Biologics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. CanSino Biologics Price Series Summation is a cross summation of CanSino Biologics price series and its benchmark/peer.
CanSino Biologics Notable Stakeholders
A CanSino Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CanSino Biologics often face trade-offs trying to please all of them. CanSino Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CanSino Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Tao Zhu | Ex CoFounder | Profile | |
| Dongxu MBA | Exec CoFounder | Profile | |
| Xuefeng Yu | Chairman, CoFounder | Profile | |
| Chunlin Xin | Director Department | Profile | |
| ShouBai Chao | COO Director | Profile | |
| Yonghui Wu | VP Marketing | Profile | |
| Xi Luo | Chief Officer | Profile | |
| FCS FCIS | Joint Sec | Profile | |
| Jing Wang | Deputy Officer | Profile |
About CanSino Biologics Management Performance
The success or failure of an entity such as CanSino Biologics often depends on how effective the management is. CanSino Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CanSino management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CanSino management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in CanSino Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CanSino Biologics. Check CanSino Biologics' Beneish M Score to see the likelihood of CanSino Biologics' management manipulating its earnings.
CanSino Biologics Workforce Analysis
Traditionally, organizations such as CanSino Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CanSino Biologics within its industry.CanSino Biologics Manpower Efficiency
Return on CanSino Biologics Manpower
| Revenue Per Employee | 477.7M | |
| Revenue Per Executive | 477.7M | |
| Net Income Per Employee | 212.7M | |
| Net Income Per Executive | 212.7M |
Additional Tools for CanSino Stock Analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.